NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma...
2021-04-14 8:30 AM EDT
NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020. Paul Brennan, NervGen's President & CEO, stated, "We made substantial progress in the development of our lead program, NVG-291, towards clinical trials...
2021-04-08 4:30 PM EDT
NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor....
2021-03-08 8:30 AM EST
NervGen Pharma Provides Regulatory Update on Development Program For NVG-291
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided a regulatory program update for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor being developed for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's...
2021-03-04 8:30 AM EST
NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer's disease patient cohort to its Phase 1 clinical trial program for its lead product, NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor....
2021-01-27 8:30 AM EST
NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer's Disease Scientific Advisory Board ("AD-SAB") with the appointment of four world-class scientists and clinical researchers in Alzheimer's disease: Jeffrey Cummings, MD, ScD;...
2021-01-26 8:30 AM EST
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6, 2021 at 3:00pm Eastern Time. Investors...
2021-01-05 8:30 AM EST
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited ("Novotech"), a leading full-service contract research organization ("CRO") in Asia-Pacific, for its upcoming Phase 1 clinical trial for NVG-291. NervGen...
2020-12-15 8:30 AM EST
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020. Paul Brennan, NervGen's President & CEO, stated, "During this past quarter, we continued working to complete the IND enabling studies...
2020-11-19 8:30 AM EST
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas,...
2020-11-10 8:30 AM EST
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Separately, NervGen announced that they were advised by its clinical research organization of a logistical delay in obtaining...
2020-10-28 8:30 AM EDT
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly Director of the U.S. Combat Casualty Care Research Program, to help NervGen identify,...
2020-10-19 8:30 AM EDT
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury and Alzheimer's disease. The NVG-291 development program is planned as follows:...
2020-10-01 7:56 PM EDT
NervGen Pharma Announces Annual General Meeting and Company Update to Be Held on September 30, 2020
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the "AGM") on Wednesday, September 30, 2020 at 2:00 p.m. PDT, as previously advised in the Company's Notice of Meeting filed with the Canadian...
2020-09-22 5:26 PM EDT
NervGen Pharma Announces Departure of Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Lloyd Mackenzie has resigned from his position as Chief Operating Officer effective October 2, 2020, in order to assume the President position of a private company not related to the focus of NervGen....
2020-09-10 8:30 AM EDT
NervGen Pharma Reports Second Quarter 2020 Results
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the second quarter ended June 30, 2020. Paul Brennan, NervGen's President & CEO, stated, "We remain very excited about the potential of our technology to treat nerve damage, whether as...
2020-08-21 8:30 AM EDT
NervGen Pharma Corp. Completes $6.45 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously announced "best efforts" public offering of 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of $6,450,000 (the "Offering"). The...
2020-08-10 9:13 AM EDT
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that it has increased the size of its previously announced common share offering. The Company intends to issue up to 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of...
2020-08-04 8:30 AM EDT
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated January 2, 2020 (the "Base Shelf Prospectus") in connection with its...
2020-07-30 8:30 AM EDT
NervGen Pharma Announces Pricing of Public Offering
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of equity securities (the "Offering"). Pursuant to the Offering, NervGen intends to issue units of the Company (the "Units") at a price of $1.75 per...
2020-07-27 8:30 AM EDT